Form 4: Halozyme Therapeutics CEO Helen Torley Reports Stock Transactions

Helen Torley, President and CEO of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and related tax withholding.

Summary

• On February 23, 2025, Helen Torley, the President and CEO of Halozyme Therapeutics, engaged in transactions involving the company's common stock.
• Torley acquired 22,436 shares of common stock through the vesting and settlement of restricted stock units (RSUs).
• Simultaneously, 12,081 shares were disposed of to cover tax withholding obligations at a price of $57.75 per share.
• Following these transactions, Torley directly owns 733,719 shares of Halozyme Therapeutics common stock.
• Torley also owns 67,308 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation. There is no indication of unusual or concerning activity.

Positives

• The vesting of restricted stock units indicates a positive incentive structure for the CEO.
• The CEO maintains a significant direct ownership stake in the company, aligning her interests with shareholders.

Negatives

• The sale of shares to cover tax obligations, while common, slightly reduces the CEO's overall holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.

Key Dates

Keywords

Halozyme Therapeutics, Helen Torley, stock transaction, Form 4, restricted stock units, RSU, beneficial ownership, derivative securities